YHR 1705

Drug Profile

YHR 1705

Alternative Names: YHR1705

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yuhan
  • Class Antihyperglycaemics; Antihyperlipidaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dyslipidaemias; Type 2 diabetes mellitus

Most Recent Events

  • 25 Jul 2017 Yuhan Corporation plans a phase I trial for Dyslipidaemias and Type-2 diabetes mellitus (In volunteers) in South Korea in August 2017(NCT03235362)
  • 25 Jul 2017 Preclinical trials in Dyslipidaemias in South Korea (PO), before August 2017 (NCT03235362)
  • 25 Jul 2017 Preclinical trials in Type-2 diabetes mellitus in South Korea (PO), before August 2017 (NCT03235362)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top